Core Insights - Resmed Inc. reported a strong start to fiscal year 2026, with a 9% year-over-year revenue growth and significant improvements in gross margins and earnings per share [2][3][5] Financial Performance - Revenue for the quarter ended September 30, 2025, was $1,335.6 million, up from $1,224.5 million in the same quarter of 2024, reflecting a 9% increase [4][5][21] - Non-GAAP gross margin improved by 280 basis points to 62.0%, while GAAP gross margin increased by 290 basis points to 61.5% [5][21] - Non-GAAP diluted earnings per share rose by 16% to $2.55, compared to $2.20 in the prior year [5][19] Operational Highlights - Income from operations increased by 15% to $446.5 million, with non-GAAP income from operations rising by 19% to $482.1 million [5][19] - Operating cash flow for the quarter was $457 million, indicating strong cash generation capabilities [5][17] - The company declared a quarterly cash dividend of $0.60 per share, payable on December 18, 2025 [8] Market and Product Insights - Revenue growth was driven by increased demand for sleep devices, masks, and accessories, with U.S., Canada, and Latin America revenue growing by 10% [9][21] - The company launched the Sleep Institute to promote sleep health as a public health priority and published a study projecting a significant increase in obstructive sleep apnea cases by 2050 [9][11] Strategic Initiatives - Resmed is committed to ongoing operational excellence and strategic investments in innovation to ensure sustainable growth [4][9] - The company recorded $16 million in restructuring-related charges as part of workforce planning aligned with its 2030 strategic priorities [9]

Core Insights - ResMed Inc reported third-quarter adjusted EPS of $2.37, slightly above the consensus estimate of $2.36 [1] - Quarterly sales rose 8% year-over-year to $1.29 billion, matching estimates, with a 9% increase on a constant currency basis [1] - Gross margin improved by 140 basis points to 59.3%, driven by manufacturing efficiencies and favorable product mix [1] Financial Performance - Adjusted operating income increased by 13% to $444.6 million [2] - Adjusted net income rose by 11% to $348.5 million [2] - Revenue in the U.S., Canada, and Latin America, excluding Residential Care Software, grew by 9% [3] - Revenue in Europe, Asia, and other markets, excluding Residential Care Software, increased by 8% on a constant currency basis [3] Product and Market Insights - Increased demand for sleep devices and growth in the Residential Care Software business contributed to sales growth [1] - Residential Care Software revenue grew by 10% on a constant currency basis, indicating continued organic growth [3] Regulatory and Analyst Commentary - Management confirmed that ResMed's products are exempt from tariffs under the Nairobi Protocol, which was approved in 2009 [2][4] - Analyst reactions include an 11% increase in ResMed stock price, with various price target adjustments from different firms [3][4]